Nasdaq
華爾街日報Why Novo Nordisk Stock Topped the Market on Thursday
Key Points
A bipartisan bill has been introduced in the U.S. Congress that would curb some activities of compound pharmacies.
The maker of Wegovy has been particularly affected by competition from such parties.
It might be best known for its weight loss drug, but Novo Nordisk (NYSE: NVO) was a gainer on the stock market Thursday. Thanks to efforts in the legislative sphere, investors were bullish on the company, and pushed into its stock to power it to a nearly 3% gain that trading session. By contrast, the S&P 500 index could only muster a 0.2% increase.
Legislative effort
Two members of the U.S. House of Representatives, Republican Rudy Yakym and Democrat Andre Carson (both of Indiana), have introduced a bill that would impose significant limitations on the making of Food and Drug Administration (FDA)-approved drugs by compounding pharmacies (i.e., those that can produce custom medicines).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
This covers the massively popular GLP-1 weight-loss drugs currently on the market, most notably Novo Nordisk's Wegovy (Eli Lilly's Zepbound also falls into this category). The compounding of GLP-1 medications has been a particular headache for Novo Nordisk, as it has increased competitive pressure on its top-selling medications.
In a joint press release issued by Yakym and Carson, the congressmen wrote that "While compounding serves important individualized medical needs, some entities are exploiting it to illegally manufacture and sell untested, unapproved drugs at scale."
"These products endanger patients, undermine trust in FDA-approved medicines, and weaken incentives to develop new treatments," they added.
Federal protection?
It's too soon to gauge the bill's chances of being passed into law, especially since Congress is dealing with more weighty matters as it heads into its holiday recess for the remainder of the year.
Still, for Novo Nordisk shareholders -- and investors in healthcare companies that either have obesity drugs on the market, like itself and Eli Lilly, or are developing the same -- it's an encouraging sign that lawmakers are willing to help protect their business from perceived threats.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.